Regenxbio (RGNX) Tops Q4 EPS by 12c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.01), $0.12 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $21.21 million versus the consensus estimate of $23.47 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Sinda opens at $10.80, IPO priced at $12
• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Wendy's (WEN) call put ratio 3.5 calls to 1 put with a focus on 2800 contracts of July 9 calls